Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical TrialRocío Montejano, Carlos Guijarro, Javier Queiruga‐Parada et al.|Clinical Infectious Diseases|2022Cited by 20
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)Sergio Serrano‐Villar, Santiago Moreno, Laura Martín‐Pedraza et al.|Clinical Infectious Diseases|2025Cited by 7